124 related articles for article (PubMed ID: 20697097)
1. Circulating miRNA signatures: promising prognostic tools for cancer.
Heneghan HM; Miller N; Kerin MJ
J Clin Oncol; 2010 Oct; 28(29):e573-4; author reply e575-6. PubMed ID: 20697097
[No Abstract] [Full Text] [Related]
2. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.
Hu Z; Chen X; Zhao Y; Tian T; Jin G; Shu Y; Chen Y; Xu L; Zen K; Zhang C; Shen H
J Clin Oncol; 2010 Apr; 28(10):1721-6. PubMed ID: 20194856
[TBL] [Abstract][Full Text] [Related]
3. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis.
Gao W; Yu Y; Cao H; Shen H; Li X; Pan S; Shu Y
Biomed Pharmacother; 2010 Jul; 64(6):399-408. PubMed ID: 20363096
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer.
Raponi M; Dossey L; Jatkoe T; Wu X; Chen G; Fan H; Beer DG
Cancer Res; 2009 Jul; 69(14):5776-83. PubMed ID: 19584273
[TBL] [Abstract][Full Text] [Related]
5. Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis.
Boeri M; Pastorino U; Sozzi G
Cancer J; 2012; 18(3):268-74. PubMed ID: 22647364
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
Patnaik SK; Kannisto E; Knudsen S; Yendamuri S
Cancer Res; 2010 Jan; 70(1):36-45. PubMed ID: 20028859
[TBL] [Abstract][Full Text] [Related]
7. First clinically useful marker for lung cancer identified.
Oncology (Williston Park); 2003 May; 17(5):737-8. PubMed ID: 12800797
[No Abstract] [Full Text] [Related]
8. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach.
Bishop JA; Benjamin H; Cholakh H; Chajut A; Clark DP; Westra WH
Clin Cancer Res; 2010 Jan; 16(2):610-9. PubMed ID: 20068099
[TBL] [Abstract][Full Text] [Related]
9. Refining prognosis in non-small-cell lung cancer.
Singh T; Dhindsa J
N Engl J Med; 2007 Jan; 356(2):190; author reply 190-1. PubMed ID: 17225287
[No Abstract] [Full Text] [Related]
10. Refining prognosis in non-small-cell lung cancer.
Sun Z; Yang P
N Engl J Med; 2007 Jan; 356(2):189-90; author reply 190-1. PubMed ID: 17215540
[No Abstract] [Full Text] [Related]
11. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
12. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer.
Wang L; Soria JC; Kemp BL; Liu DD; Mao L; Khuri FR
Clin Cancer Res; 2002 Sep; 8(9):2883-9. PubMed ID: 12231532
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.
Takamizawa J; Konishi H; Yanagisawa K; Tomida S; Osada H; Endoh H; Harano T; Yatabe Y; Nagino M; Nimura Y; Mitsudomi T; Takahashi T
Cancer Res; 2004 Jun; 64(11):3753-6. PubMed ID: 15172979
[TBL] [Abstract][Full Text] [Related]
14. Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer.
Adachi M; Taki T; Higashiyama M; Kohno N; Inufusa H; Miyake M
Clin Cancer Res; 2000 Jan; 6(1):96-101. PubMed ID: 10656437
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor polymorphisms in early-stage non-small-cell lung cancer.
Patel M; Ailawadhi S; Hernandez-Ilizaliturri F; Wilding GE
J Clin Oncol; 2008 Jul; 26(19):3289-90; author reply 3290. PubMed ID: 18591568
[No Abstract] [Full Text] [Related]
16. [Association of molecular biology of lung cancers and their metastasis and prognosis].
Mao YS; Gao YN; He J
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):632-4. PubMed ID: 17236563
[No Abstract] [Full Text] [Related]
17. Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer.
Yang J; Tan D; Asch HL; Swede H; Bepler G; Geradts J; Moysich KB
Lung Cancer; 2004 Oct; 46(1):29-42. PubMed ID: 15364130
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA signature predicts survival and relapse in lung cancer.
Yu SL; Chen HY; Chang GC; Chen CY; Chen HW; Singh S; Cheng CL; Yu CJ; Lee YC; Chen HS; Su TJ; Chiang CC; Li HN; Hong QS; Su HY; Chen CC; Chen WJ; Liu CC; Chan WK; Chen WJ; Li KC; Chen JJ; Yang PC
Cancer Cell; 2008 Jan; 13(1):48-57. PubMed ID: 18167339
[TBL] [Abstract][Full Text] [Related]
19. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer.
Roepman P; Jassem J; Smit EF; Muley T; Niklinski J; van de Velde T; Witteveen AT; Rzyman W; Floore A; Burgers S; Giaccone G; Meister M; Dienemann H; Skrzypski M; Kozlowski M; Mooi WJ; van Zandwijk N
Clin Cancer Res; 2009 Jan; 15(1):284-90. PubMed ID: 19118056
[TBL] [Abstract][Full Text] [Related]
20. [Flow cytometric analysis of the DNA content of resected non-small cell lung cancer with reference to long-term follow-up].
Nagai S; Chiba W; Ikeda S; Matsumoto H; Fujimoto T; Ishida H; Wazawa H; Hanawa T; Yamashita N; Yasuda Y; Matsubara Y; Hatakenaka R; Funatsu T
Gan To Kagaku Ryoho; 1996 Jun; 23 Suppl 2():130-4. PubMed ID: 8678555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
